Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.

Virchows Archiv : an international journal of pathology - 1 Jul 2023

McHenry Austin, Rottmann Douglas A, Buza Natalia, Hui Pei

Abstract excerpt

Oncogenic activation of the mitogen-activated protein kinase (MAPK) pathway due to KRAS or BRAF gain-of-function mutation is frequently found in ovarian serous borderline tumor (SBT) and their extraovarian implants. We investigated mutational status of KRAS and BRAF of the primary ovarian SBTs that had a high stage presentation in correlation with clinical outcome. Among 39 consecutive primary SBTs with either...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystadenocarcinoma, Serous
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Ovarian Neoplasms

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 37219599
DOI: 10.1007/s00428-023-03564-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.PMID 37219599Read ↗

KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.Semantic proximity Read ↗

KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.Semantic proximity Read ↗

The molecular pathology of ovarian serous borderline tumors.Semantic proximity Read ↗

KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.Semantic proximity Read ↗

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.Semantic proximity Read ↗

Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.Semantic proximity Read ↗

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.Semantic proximity Read ↗

Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors.Semantic proximity Read ↗

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.Semantic proximity Read ↗

v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior.Semantic proximity Read ↗

Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.Semantic proximity Read ↗

Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.